Therapeutic Controlled Release Strategies for Human Osteoarthritis

Osteoarthritis is a progressive, irreversible debilitating whole joint disease that affects millions of people worldwide. Despite the availability of various options (non‐pharmacological and pharmacological treatments and therapy, orthobiologics, and surgical interventions), none of them can definit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced healthcare materials 2025-01, Vol.14 (2), p.e2402737-n/a
Hauptverfasser: Wang, Dan, Liu, Wei, Venkatesan, Jagadeesh K., Madry, Henning, Cucchiarini, Magali
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Osteoarthritis is a progressive, irreversible debilitating whole joint disease that affects millions of people worldwide. Despite the availability of various options (non‐pharmacological and pharmacological treatments and therapy, orthobiologics, and surgical interventions), none of them can definitively cure osteoarthritis in patients. Strategies based on the controlled release of therapeutic compounds via biocompatible materials may provide powerful tools to enhance the spatiotemporal delivery, expression, and activities of the candidate agents as a means to durably manage the pathological progression of osteoarthritis in the affected joints upon convenient intra‐articular (injectable) delivery while reducing their clearance, dissemination, or side effects. The goal of this review is to describe the current knowledge and advancements of controlled release to treat osteoarthritis, from basic principles to applications in vivo using therapeutic recombinant molecules and drugs and more innovatively gene sequences, providing a degree of confidence to manage the disease in patients in a close future. Therapeutic controlled release is a promising approach to treat the progressive and irreversible pathological changes in human osteoarthritis. This strategy is based on the application of recombinant molecules, drugs, and gene sequences via biocompatible materials and may provide effective and long‐lasting tools promoting the spatiotemporal delivery, expression, and activities of candidate agents in the affected joints.
ISSN:2192-2640
2192-2659
2192-2659
DOI:10.1002/adhm.202402737